AB-CHMINACA

NameAB-CHMINACA
Formal NameN-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1- (cyclohexylmethyl)- 1H-indazole-3-carboxamide
SMILESO=C(N[C@H](C(N)=O)C(C)C)C1=NN(CC2CCCCC2)C3=C1C=CC=C3
InChI KeyKJNZIEGLNLCWTQ-KRWDZBQOSA-N
InChI CodeInChI=1S/C20H28N4O2/c1-13(2)17(19(21)25)22-20(26)18-15-10-6-7-11-16(15)24(23-18)12-14-8- 4-3-5-9-14/h6-7,10-11,13-14,17H,3-5,8-9,12H2,1-2H3,(H2,21,25)(H,22,26)/t17-/m0/s1
DescriptionAB-CHMINACA is a cannabinoid receptor modulator that was first synthesized by Pfizer for its potential therapeutic use. The Ki toward the CB1 receptor was reported in a 2009 patent to be 0.5 nM.1 AB-CHMINACA is one of many new designer drugs being detected in illegal spice/herbal products. AB-CHMINACA is structurally related to another Pfizer cannabinoid, AB-FUBINACA, in that the p-fluorophenyl group has been replaced with a cyclohexyl group. AB-FUBINACA is a similarly potent CB1 receptor modulator that is now a US DEA regulated Schedule I controlled substance (Drug Code 7012) after having been identified in illegal products.

Status

Verified
Submitted2014-06-01
Submitted ByCayman Chemical
Kentucky State Police Eastern Laboratory Branch, Ashland, KY
Published2014-07-22
ContactPaul D. Kennedy, PhD. at Cayman Chemical
Product DetailsLink

Monograph

Download the AB-CHMINACA Monograph